Invasive lung squamous cell carcinoma (LUSC) accounts for approximately one-quarter of all lung cancers, but therapeutic ...
The Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the adjuvant, or postsurgical, treatment of ...
The FDA has approved cemiplimab as an adjuvant treatment for high-risk cutaneous squamous cell carcinoma. The US FDA has ...
Our analysis of currently available data regarding imiquimod (Aldara) is that it can likely be used in renal transplant recipients without incurring a probable risk of acute rejection. However, ...
Libtayo's FDA approval offers an effective adjuvant option for high-risk cutaneous squamous cell carcinoma, reducing ...
SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S.
C5aR1 expression correlates with increased metastasis risk and poor survival in cSCC patients. The tumor microenvironment, especially fibroblasts, influences C5aR1 expression and cSCC progression.
Comparing metagenomic profiles of the skin microbiome in immunosuppressed patients and those at high and low risk for cutaneous squamous cell carcinoma (SCC) revealed distinct expansions in fungal and ...
Skin malignancies are the most common cancers in the United States. 1 Typically, skin cancer is categorized as either melanoma or nonmelanoma skin cancer, which is also known as keratinocyte ...
The FDA has approved cemiplimab-rwlc for adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback